Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial

被引：0

作者：

Motzer, Robert J.

Penkov, Konstantin

Uemura, Hirotsugu

Campbell, Matthew T.

Kollmannsberger, Christian K.

Lee, Jae-Lyun

Venugopal, Balaji

Van Den Eertwegh, Alfonsus

Negrier, Sylvie

Gurney, Howard

Albiges, Laurence

Berger, Raanan

Haanen, John

Rini, Brian I.

Larkin, James

Schmidinger, Manuela

Sandner, Robin

Wang, Jing

Di Pietro, Alessandra

Choueiri, Toni K.

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Private Med Inst, Euromed Serv, St Petersburg, Russia

[3] Kindai Univ, Dept Urol, Fac Med, Osaka, Japan

[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Genitourinary Med Oncol, Houston, TX USA

[5] British Columbia Canc Agcy, Vancouver Ctr, Vancouver, BC, Canada

[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[7] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[8] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Amsterdam, Netherlands

[9] Univ Lyon, Lyon, France

[10] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia

[11] Inst Gustave Roussy, Villejuif, France

[12] Chaim Sheba Med Ctr, Ramat Gan, Israel

[13] Netherlands Canc Inst, Amsterdam, Netherlands

[14] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[15] Royal Marsden Hosp NHS Fdn Trust, London, England

[16] Med Univ Vienna, Vienna, Austria

[17] Pfizer Inc, Collegeville, PA USA

[18] Pfizer Inc, Cambridge, MA USA

[19] Pfizer SRL, Milan, Italy

[20] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4508

引用

页数：1

共 50 条

[41] Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
Atkins, Michael
Martini, Jean-Francois
Plimack, Elizabeth
McDermott, David
Puzanov, Igor
Fishman, Mayer
Cho, Daniel
Vaishampayan, Ulka
Rosbrook, Brad
Fernandez, Kathrine
Tarazi, Jamal
George, Saby
Choueiri, Toni
CANCER RESEARCH, 2019, 79 (13)
[42] AXITINIB VS SORAFENIB FOR ADVANCED RENAL CELL CARCINOMA: PHASE III OVERALL SURVIVAL RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS
Motzer, R. J.
Escudier, B.
Tomczak, P.
Negrier, S.
Gore, M. E.
Tarazi, J.
Hariharan, S.
Rosbrook, B.
Kim, S.
Rini, B. I.
ANNALS OF ONCOLOGY, 2012, 23 : 262 - 262
[43] Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
Tomita, Y.
Larkin, J.
Venugopal, B.
Haanen, J.
Kanayama, H.
Eto, M.
Grimm, M-O
Fujii, Y.
Umeyama, Y.
Huang, B.
Mariani, M.
di Pietro, A.
Choueiri, T. K.
ESMO OPEN, 2022, 7 (05)
[44] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
Porta, C. G.
Eto, M.
Motzer, R. J.
De Giorgi, U. F. F.
Buchler, T.
Basappa, N. S.
Mendez Vidal, M. J.
Tjulandin, S.
Park, S. H.
Melichar, B.
Hutson, T. E.
Alemany, C.
McGregor, B.
He, C. S.
Perini, R.
Mody, K.
McKenzie, J.
Choueiri, T. K.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
[45] Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
Choueiri, Toni K.
Motzer, Robert J.
Powles, Thomas
Burotto, Mauricio
Apolo, Andrea B.
Escudier, Bernard
McDermott, David F.
Braun, David A.
Han, Celine
Lee, George
Dwivedi, Bhakti
Li, Jun
Gupta, Saurabh
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[46] Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214
Gruenwald, Viktor
Choueiri, Toni K.
Rini, Brian I.
Powles, Thomas
George, Saby
Grimm, Marc-Oliver
Mchenry, M. Brent
Maurer, Matthew
Motzer, Robert J.
Hammers, Hans J.
Tannir, Nizar M.
Albiges, Laurence
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 74 - 75
[47] Avelumab plus axitinib (Ave plus Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Venugopal, B.
Choueiri, T. K.
Penkov, K. D.
Albiges, L.
Uemura, H.
Larkin, J.
Tomita, Y.
Wang, J.
Hoffman, J.
Gerhold-Ay, A.
Kieslich, P.
Motzer, R. J.
ANNALS OF ONCOLOGY, 2024, 35 : S1017 - S1018
[48] Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
Tomita, Y.
Motzer, R. J.
Choueiri, T. K.
Rini, B. I.
Miyake, H.
Oya, M.
Albiges, L.
Aizawa, M.
Umeyama, Y.
Wang, J.
di Pietro, A.
Schmidinger, M.
ESMO OPEN, 2023, 8 (06)
[49] Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
Gruenwald, V
Motzer, R. J.
Sharma, P.
Escudier, B.
McDermott, D. F.
George, S.
Srinivas, S.
Tykodi, S. S.
Sosman, J. A.
Plimack, E. R.
Nathan, P.
Tomita, Y.
Zhao, H.
Waxman, I. M.
Hammers, H. J.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 264 - 265
[50] Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study
Motzer, Robert J.
Sharma, Padmanee
Escudier, Bernard J.
McDermott, David F.
George, Saby
Srinivas, Sandy
Tykodi, Scott S.
Sosman, Jeffrey Alan
Plimack, Elizabeth R.
Nathan, Paul D.
Gruenwald, Viktor
Tomita, Yoshihiko
Zhao, Huanyu
Waxman, Ian M.
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →